PATENT CLAIM ANALYSIS

Application Number: 15895055
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["424", "173100"]

Abstract:
Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.

Claim (Index 3):
A method for treating a disease or disorder that is mediated by BAFF receptor or that can be treated by killing or depleting B cells, comprising administering to a subject the aqueous pharmaceutical composition of  claim 1 .

Metadata:
- Claim Count in Document: 14.0
- Percentile: 88.0
- Lexical Diversity: 1.59322
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13991984', '13912355', '14942388', '15881195', '14114835']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7344988796442387
- 35 USC 102 Novelty (BERT): 0.6293526808949643
- Combined Prediction Score: 0.7239842597693112
- Mean Citation Score: 492.277956
- Max Citation Score: 578.80133
- Similarity Product: 541.9216342405845

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test